| Revision as of 20:09, 26 December 2024 editA455bcd9 (talk | contribs)Extended confirmed users20,601 editsNo edit summaryTag: 2017 wikitext editor← Previous edit | Revision as of 20:09, 26 December 2024 edit undoA455bcd9 (talk | contribs)Extended confirmed users20,601 editsNo edit summaryTag: 2017 wikitext editorNext edit → | ||
| Line 1: | Line 1: | ||
| '''Neuronal Alpha-Synuclein Disease''' is a proposed new combined definition of ] and ] based on <ref>{{Cite web |title=Major Shift in the Clinical Definition of PD Triggers Debate |url=https://www.medscape.com/viewarticle/major-shift-clinical-definition-parkinsons-triggers-debate-2024a1000cv1?form=fpf |access-date=2024-12-26 |website=Medscape |language=en}}</ref><ref>{{cite web|url=https://www.medpagetoday.com/neurology/parkinsonsdisease/108446|title=New Parkinson's Definition Proposed Based on Biomarkers|date=January 26, 2024}}</ref><ref>{{Cite journal |last=Simuni |first=Tanya |last2=Chahine |first2=Lana M |last3=Poston |first3=Kathleen |last4=Brumm |first4=Michael |last5=Buracchio |first5=Teresa |last6=Campbell |first6=Michelle |last7=Chowdhury |first7=Sohini |last8=Coffey |first8=Christopher |last9=Concha-Marambio |first9=Luis |last10=Dam |first10=Tien |last11=DiBiaso |first11=Peter |last12=Foroud |first12=Tatiana |last13=Frasier |first13=Mark |last14=Gochanour |first14=Caroline |last15=Jennings |first15=Danna |date=2024-02-01 |title=A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research |url=https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00405-2/fulltext |journal=The Lancet Neurology |language=English |volume=23 |issue=2 |pages=178–190 |doi=10.1016/S1474-4422(23)00405-2 |issn=1474-4422 |archive-url=http://web.archive.org/web/20240201122650/https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00405-2/fulltext |archive-date=2024-02-01}}</ref><ref>{{Cite journal |last=Pagano |first=Gennaro |last2=Dam |first2=Tien |last3=Kerchner |first3=Geoffrey A. |last4=Galpern |first4=Wendy R. |last5=Biagioni |first5=Milton |last6=Karan |first6=Rajesh |last7=Jennings |first7=Danna |last8=Peterschmitt |first8=M. Judith |last9=Nikolcheva |first9=Tania |last10=Brundin |first10=Patrik |date=2024-12-20 |title=Biologically defined neuronal synuclein disease as a tool to advance drug development |url=https://www.nature.com/articles/s41531-024-00845-5 |journal=npj Parkinson's Disease |language=en |volume=10 |issue=1 |pages=1–3 |doi=10.1038/s41531-024-00845-5 |issn=2373-8057}}</ref> | '''Neuronal Alpha-Synuclein Disease''' is a proposed new combined definition of ] and ] based on biology instead of ].<ref>{{Cite web |title=Major Shift in the Clinical Definition of PD Triggers Debate |url=https://www.medscape.com/viewarticle/major-shift-clinical-definition-parkinsons-triggers-debate-2024a1000cv1?form=fpf |access-date=2024-12-26 |website=Medscape |language=en}}</ref><ref>{{cite web|url=https://www.medpagetoday.com/neurology/parkinsonsdisease/108446|title=New Parkinson's Definition Proposed Based on Biomarkers|date=January 26, 2024}}</ref><ref>{{Cite journal |last=Simuni |first=Tanya |last2=Chahine |first2=Lana M |last3=Poston |first3=Kathleen |last4=Brumm |first4=Michael |last5=Buracchio |first5=Teresa |last6=Campbell |first6=Michelle |last7=Chowdhury |first7=Sohini |last8=Coffey |first8=Christopher |last9=Concha-Marambio |first9=Luis |last10=Dam |first10=Tien |last11=DiBiaso |first11=Peter |last12=Foroud |first12=Tatiana |last13=Frasier |first13=Mark |last14=Gochanour |first14=Caroline |last15=Jennings |first15=Danna |date=2024-02-01 |title=A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research |url=https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00405-2/fulltext |journal=The Lancet Neurology |language=English |volume=23 |issue=2 |pages=178–190 |doi=10.1016/S1474-4422(23)00405-2 |issn=1474-4422 |archive-url=http://web.archive.org/web/20240201122650/https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00405-2/fulltext |archive-date=2024-02-01}}</ref><ref>{{Cite journal |last=Pagano |first=Gennaro |last2=Dam |first2=Tien |last3=Kerchner |first3=Geoffrey A. |last4=Galpern |first4=Wendy R. |last5=Biagioni |first5=Milton |last6=Karan |first6=Rajesh |last7=Jennings |first7=Danna |last8=Peterschmitt |first8=M. Judith |last9=Nikolcheva |first9=Tania |last10=Brundin |first10=Patrik |date=2024-12-20 |title=Biologically defined neuronal synuclein disease as a tool to advance drug development |url=https://www.nature.com/articles/s41531-024-00845-5 |journal=npj Parkinson's Disease |language=en |volume=10 |issue=1 |pages=1–3 |doi=10.1038/s41531-024-00845-5 |issn=2373-8057}}</ref> | ||
Revision as of 20:09, 26 December 2024
Neuronal Alpha-Synuclein Disease is a proposed new combined definition of Parkinson's disease and Lewy Body dementia based on biology instead of symptomatology.
- "Major Shift in the Clinical Definition of PD Triggers Debate". Medscape. Retrieved 2024-12-26.
- "New Parkinson's Definition Proposed Based on Biomarkers". January 26, 2024.
- Simuni, Tanya; Chahine, Lana M; Poston, Kathleen; Brumm, Michael; Buracchio, Teresa; Campbell, Michelle; Chowdhury, Sohini; Coffey, Christopher; Concha-Marambio, Luis; Dam, Tien; DiBiaso, Peter; Foroud, Tatiana; Frasier, Mark; Gochanour, Caroline; Jennings, Danna (2024-02-01). "A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research". The Lancet Neurology. 23 (2): 178–190. doi:10.1016/S1474-4422(23)00405-2. ISSN 1474-4422. Archived from the original on 2024-02-01.
- Pagano, Gennaro; Dam, Tien; Kerchner, Geoffrey A.; Galpern, Wendy R.; Biagioni, Milton; Karan, Rajesh; Jennings, Danna; Peterschmitt, M. Judith; Nikolcheva, Tania; Brundin, Patrik (2024-12-20). "Biologically defined neuronal synuclein disease as a tool to advance drug development". npj Parkinson's Disease. 10 (1): 1–3. doi:10.1038/s41531-024-00845-5. ISSN 2373-8057.